Silexion Therapeutics Statistics Share Statistics Silexion Therapeutics has 579.49K
shares outstanding. The number of shares has increased by -11.02%
in one year.
Shares Outstanding 579.49K Shares Change (YoY) -11.02% Shares Change (QoQ) 3.3% Owned by Institutions (%) n/a Shares Floating 527.06K Failed to Deliver (FTD) Shares 4,061 FTD / Avg. Volume 4.53%
Short Selling Information The latest short interest is 619.43K, so 7.13% of the outstanding
shares have been sold short.
Short Interest 619.43K Short % of Shares Out 7.13% Short % of Float 7.56% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is 11.39 and the forward
PE ratio is -0.51.
Silexion Therapeutics's PEG ratio is
-0.28.
PE Ratio 11.39 Forward PE -0.51 PS Ratio 0 Forward PS n/a PB Ratio -47.15 P/FCF Ratio -22.34 PEG Ratio -0.28
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Silexion Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.64,
with a Debt / Equity ratio of -1.13.
Current Ratio 0.64 Quick Ratio 0.64 Debt / Equity -1.13 Debt / EBITDA -0.27 Debt / FCF -0.53 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $1.5M Employee Count 11 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 10K Effective Tax Rate -0.06%
Stock Price Statistics The stock price has increased by null% in the
last 52 weeks. The beta is 0.08, so Silexion Therapeutics's
price volatility has been higher than the market average.
Beta 0.08 52-Week Price Change n/a 50-Day Moving Average 12.33 200-Day Moving Average 21.66 Relative Strength Index (RSI) 36.63 Average Volume (20 Days) 89,654
Income Statement
Revenue n/a Gross Profit n/a Operating Income -12.57M Net Income 16.51M EBITDA -16.43M EBIT -16.46M Earnings Per Share (EPS) -2.64
Full Income Statement Balance Sheet The company has 1.19M in cash and 4.49M in
debt, giving a net cash position of -3.3M.
Cash & Cash Equivalents 1.19M Total Debt 4.49M Net Cash -3.3M Retained Earnings -43.25M Total Assets 8.31M Working Capital 5.33M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -8.4M
and capital expenditures -22K, giving a free cash flow of -8.42M.
Operating Cash Flow -8.4M Capital Expenditures -22K Free Cash Flow -8.42M FCF Per Share -1.35
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields SLXN does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for SLXN is $75,
which is 920.4% higher than the current price. The consensus rating is "Buy".
Price Target $75 Price Target Difference 920.4% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 29, 2025. It was a
backward
split with a ratio of 1:15.
Last Split Date Jul 29, 2025 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -13.04 Piotroski F-Score 2
